BioMarin Pharmaceutical Inc - Company Profile
Powered by 
All the sales intelligence you need on BioMarin Pharmaceutical Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioMarin Pharmaceutical Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioMarin Pharmaceutical Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioMarin Pharmaceutical Inc (BioMarin) is a biotechnology company. It focuses on the research, development, and commercialization of medicines to address rare or difficult genetic disorders. BioMarin's major products include therapies for conditions such as mucopolysaccharidosis, achondroplasia, phenylketonuria, severe hemophilia A, and neuronal ceroid lipofuscinosis type 2 diseases, among others. BioMarin's products are offered to patients through hospitals, non-US government agencies, authorized distributors, and certain larger pharmaceutical wholesalers under the brands Vimizim, Palynziq, Brineura, and Kuvan. The company distributes its products in the Americas, Asia, the Middle East, and Europe. It operates manufacturing facilities in the US and Ireland. BioMarin is headquartered in San Rafael, California, the US.
Headquarters
United States of America
Address
770 Lindaro Street, San Rafael, California, 94901
Website
www.biomarin.com
Telephone
1 415 5056700
No of Employees
3,221
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BMRN (NASD)
Revenue (2024)
$3.2B
12.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-18.3%
(2024 vs 2023)
Market Cap*
$11.4B
Net Profit Margin (2024)
XYZ
-27.6%
(2024 vs 2023)
* As of and is in US$
BioMarin Pharmaceutical Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Commercialized | Voxzogo |
| Elosulfase Alpha: Mucopolysaccharidosis (MPS) IVA | BioMarin |
| Galsulfase: MPS VI | Brineura |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In April, the company acquired Amicus Therapeutics for US$4.8 billion. |
| 2026 | Regulatory Approval | In February, the company received approval from the US FDA for Palynziq (pegvaliase-pqpz) for adolescents 12 years of age and older with phenylketonuria (PKU). |
| 2026 | Contracts/Agreements | In January, the company expanded its partnership with Veeva Systems to leverage Veeva’s software, data, and services to enhance BioMarin’s speed, efficiency, and HCP/patient experience. |
Competitor Comparison
| Key Parameters | BioMarin Pharmaceutical Inc | Novo Nordisk AS | Takeda Pharmaceutical Co Ltd | Biogen Inc | Sarepta Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Denmark | Japan | United States of America | United States of America |
| City | San Rafael | Bagsvaerd | Chuo-Ku | Cambridge | Cambridge |
| State/Province | California | - | Tokyo | Massachusetts | Massachusetts |
| No. of Employees | 3,221 | 64,974 | 47,455 | 7,500 | 835 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ian T. Clark | Chairman | Executive Board | 2026 | - |
| Alexander Hardy | Director; President; Chief Executive Officer | Executive Board | 2023 | 57 |
| Brian R. Mueller | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 52 |
| C. Greg Guyer, PhD | Chief Technology Officer; Executive Vice President | Senior Management | 2020 | 64 |
| G. Eric Davis | Executive Vice President; Secretary; Chief Legal Officer | Senior Management | 2022 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer